Hidradenitis Suppurativa Drugs

Sep 27, 2024

Imagine a world where treatment options are as precise as a scalpel and as adaptable as a chameleon. Bispecific antibodies are paving the way for this future, bringing revolutionary advancements not just in oncology but across various therapeutic fields. By harnessing the power of these dual-targeting agents, resea...

Sep 13, 2024

Currently, leading hidradenitis suppurativa drugs on the market include UCB Biopharma’s BIMZELX (bimekizumab), Novartis’ COSENTYX (secukinumab), and AbbVie/Eisai’s HUMIRA (adalimumab). HUMIRA dominated the market until 2023, despite its US composition-of-matter patent expiring in December 2016. AbbVie maintained a ...

Sep 06, 2024

Hidradenitis suppurativa is a chronic inflammatory skin disease that affects the hair follicles and apocrine sweat glands. Hidradenitis suppurativa affects approximately 1% of the population, with women being more commonly affected than men. It often begins after puberty, usually in the 20s or 30s. In 2023, the ...